Oral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis
MetadataShow full item record
AbstractBackground: The concept of maintenance therapy in cancer treatment is currently under debate because of modest survival benefits, added toxicity, economic considerations, and quality-of-life concerns. Traditional Chinese Medicine (tcm) is widely used in China for cancer patients, offering the advantages of low toxicity and enhancement of quality of life. However, no systematic reviews or meta-analyses have assessed the role of tcm as maintenance treatment for non-small-cell lung carcinoma. Methods: We searched the Chinese Biomedical Literature Database, the China National Knowledge Infrastructure, PubMed, embase, and the Cochrane Library databases for all eligible studies. The endpoints were overall survival (os), progression-free survival (pfs), the 1-year and 2-year survival rates, and performance status. Our meta-analysis used a fixed-effects model and a random-effects model for heterogeneity in the Stata software application (version 11.0: StataCorp LP, College Station, TX, U.S.A.), with the results expressed as hazard ratios (hrs) or risk ratios (rrs), with their corresponding 95% confidence intervals (95% cis). Results: Sixteen randomized studies representing 1150 patients met the inclusion criteria. Compared with best supportive care, observation, or placebo, tcm as maintenance treatment was associated with a significant increase in os (hr: 0.49; 95% ci: 0.35 to 0.68; p < 0.001), pfs (hr: 0.66; 95% ci: 0.51 to 0.84; p = 0.001), and 2-year survival rate (rr: 0.63; 95% ci: 0.44 to 0.92, p = 0.017), and a significant improvement in performance status (rr: 0.68; 95% ci: 0.61 to 0.75; p < 0.001). Conclusions: For patients who show non-progression—including stable disease, partial response, or complete response—after first-line chemotherapy, including those with poor quality of life, oral Chinese herbal medicine can be considered an efficient and safe maintenance therapy strategy. Copyright 2017 Multimed Inc.
SponsorsThis study was funded by the Shanghai Minhang Municipal Planning Commission of Science and Research Fund (no. 2014MW24); the National Natural Science Fund (no. 81072740); the National Scientific Research Project of National Traditional Chinese Medicine (no. 201307006); the Science and Technology Commission of Shanghai Municipality (nos. 16401970700, 16401970701, 16401970704); and the Fund of Shanghai University of Traditional Chinese Medicine (no. 2015YSN37).
Non-small-cell lung cancer
Traditional Chinese medicine
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85028649011&doi=10.3747%2fco.24.3561&partnerID=40&md5=8d436bd55e2ee2b9afd3dbf5057576ac; http://hdl.handle.net/10713/9933
- Astragalus-containing Traditional Chinese Medicine, with and without prescription based on syndrome differentiation, combined with chemotherapy for advanced non-small-cell lung cancer: a systemic review and meta-analysis.
- Authors: Wang SF, Wang Q, Jiao LJ, Huang YL, Garfield D, Zhang J, Xu L
- Issue date: 2016 Jun
- Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: A randomized controlled trial.
- Authors: Jiang Y, Liu LS, Shen LP, Han ZF, Jian H, Liu JX, Xu L, Li HG, Tian JH, Mao ZJ
- Issue date: 2016 Feb
- Systematic review and meta-analysis of Chinese herbal medicine as adjuvant treatment in advanced non-small cell lung cancer patients.
- Authors: Wang LC, Chang YY, Lee IC, Kuo HC, Tsai MY
- Issue date: 2020 Aug
- Kanglaite injection plus chemotherapy versus chemotherapy alone for non-small cell lung cancer patients: A systematic review and meta-analysis.
- Authors: Liu X, Xu F, Wang G, Diao X, Li Y
- Issue date: 2008 Oct
- Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis.
- Authors: Behera M, Owonikoko TK, Chen Z, Kono SA, Khuri FR, Belani CP, Ramalingam SS
- Issue date: 2012 Aug